3Vote!
Patent Docs (Free subscription) | 20/11/2009
By Kevin E. Noonan -- Christopher M. Holman, Associate Professor of Law at the University of Missouri-Kansas City (and proprietor of Holman's Biotech IP Blog), has filed an amicus brief in support of neither party in Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co. While not arguing on behalf of either party, Ariad would benefit if the Federal Circuit adopts Professor Holman's position: he not only...
3Vote!
Patent Docs (Free subscription) | 20/11/2009
Christopher M. Holman, Associate Professor of Law at the University of Missouri-Kansas City (and proprietor of Holman's Biotech IP blog, www.holmansbiotechipblog.com), has filed an amicus brief in support of neither party in Ariad v. Eli Lilly & Co. While not arguing on behalf of either party, Ariad would benefit if the court adopts Professor Holman's position: he not only advocates that there...
3Vote!
PharmaGossip (Free subscription) | 20/11/2009
Justice Department Recovers $2.4 Billion in False Claims Cases in Fiscal Year 2009; More Than $24 Billion Since 1986 FY09 Recovery is Second Largest in History WASHINGTON, Nov. 19 /PRNewswire-USNewswire/ -- The United States secured $2.4 billion in settlements and judgments in cases involving fraud against the government in the fiscal year ending Sept. 30, 2009, the Justice Department announced today....
3Vote!
Indy Star (Free subscription) | 19/11/2009
A top research executive at Eli Lilly and Co. will collect $2 million in severance after he retires in February, the Indianapolis drugmaker disclosed today in a regulatory filing.
3Vote!
In the Pipeline (Free subscription) | 19/11/2009
The InVivo Blog has a good article on a controversy in the blood-thinning market. Plavix (clopidogrel) has a very strong share of that, of course, but since Effient (prasugrel) was finally approved, Lilly and Dai-Ichii are looking to take as much of that market as they can. And one opening might be that not everyone responds similarly to Plavix. In some cases, that's because there are some drug-drug...
3Vote!
The IN VIVO Blog (Free subscription) | 19/11/2009
The Food & Drug Administration's public health alert on Plavix is, as we point out in "The Pink Sheet" DAILY , a nice boost for Eli Lilly and Daiichi Sankyo, who market the competing platelet agent Effient . But the back story to this regulatory action merits closer attention by all pharmaceutical sponsors. This is no ordinary labeling change, and the implications of how the regulatory...
3Vote!
Xconomy (Free subscription) | 19/11/2009
Three years have gone by since the region’s top biotech company was taken over by Eli Lilly, so it seemed like a good time to find out where all that talent migrated around the Northwest. —Icos was once the great hope for Seattle biotech, but now three years have passed since the Bothell, WA-based company agreed [...]
3Vote!
Fiercebiotech (Free subscription) | 18/11/2009
I have rarely interviewed a biotech executive who wasn't trying to figure out some way to cut back on the time and expense of a clinical trial. For most, it's a question of lean staffing and savvy outsourcing work. And while that's key, there's been a lot of work being done on adaptive clinical trials, biomarkers and more that is aimed at giving biotech developers the tools they need to rein in costs....
3Vote!
Capital Observer (Free subscription) | 18/11/2009
The hardest thing for me is to just hold onto stocks that are doing well for me. My pharmaceutical positions continue to march higher and I have to fight off the urge to book profits every day. I own Merck, Pfizer and Eli Lilly and all seem to have broken out over the past few days. I sold covered call earlier in the month and partial positions will likely be taken away from me on expiration.
3Vote!
Fiercebiotech (Free subscription) | 18/11/2009
Peter Thompson , Trubion Pharmaceuticals' president, CEO, chairman of the board and co-founder, has retired. Steven Gillis , former lead director of Trubion's board, has been appointed executive chairman of the board and acting president. Michelle Burris , Trubion's senior vice president and chief financial officer, will assume the role of chief operating officer, and John Bencich , the company's...
Explore : AstraZeneca,
Bausch and Lomb,
Biology,
Channels,
Discovery,
Drug Manufacturers,
Generic Drugs,
Health Industries,
Medical Products and Supplies,
Merck,
Watson Pharmaceuticals
3Vote!
Market Watch (Free subscription) | 18/11/2009
BOSTON (MarketWatch) -- Vivus Inc. early Wednesday reported positive Phase III clinical results for its new drug avanafil for the treatment of erectile dysfunction, or ED. "These Phase III avanafil data not only confirm the robust efficacy we've seen in earlier trials, but potentially differentiate avanafil from other PDE5 inhibitors when it comes to side effects and time-to-onset of efficacy,"...
3Vote!
Findlaw (Free subscription) | 17/11/2009
As we previously discussed regarding Eli Lilly's $1.42 Billion Zyprexa settlement, major pharmaceutical company Eli Lilly has faced a host of suits over its marketing tactics for the drug Zyprexa. Last week Utah Attorney General, Mark Shurtleff, announced that state's...
3Vote!
Market Wire (Free subscription) | 17/11/2009
NEW YORK, NY (MARKET WIRE) Cycle Computing, providing proven, secure and flexible high performance computing (HPC) and open source solutions in the cloud, today announced that the increasing enterprise demand for HPC and cloud computing is fueling its rapid expansion across industries. Cycle helps cutting-edge companies across market segments, including Eli Lilly, Pfizer and Varian Inc. in the pharmaceutical...
3Vote!
Bioethics.net (Free subscription) | 17/11/2009
In the first half of this year, the drug giant Eli Lilly paid 3,971 doctors and other medical professionals an average of about $11,230 each. The payments were for participating in an average of 12 speaking or consulting engagements during those six months, according to a company spokeswoman.
3Vote!
Patent Docs (Free subscription) | 17/11/2009
By Donald Zuhn -- Last week, Defendant-Appellant Eli Lilly & Co. filed its principal brief for the rehearing en banc of Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., which is scheduled for December 7th. (Patent Docs provided a summary of Ariad's principal brief, which was filed on October 5th, last Tuesday; see "Next Up: Ariad v. Lilly Rehearing En Banc.") In response to the two...
Videos